Isoconazole nitrate + Diflucortolone valerate
The medicine contains two active substances: isoconazole nitrate and diflucortolone valerate.
Isoconazole nitrate treats fungal skin diseases.
Diflucortolone valerate belongs to a group of medicines called corticosteroids with strong effects, reduces
skin inflammation and alleviates symptoms such as itching, burning, pain.
Travocort is indicated for the initial treatment of superficial fungal skin infections with concomitant severe
inflammatory or eczematous skin changes, e.g. on the hands, interdigital spaces of the feet and the groin
and genital areas.
Before starting treatment with Travocort, discuss it with your doctor or pharmacist.
Particularly careful and short-term use is recommended on the skin of the face and in children. In children,
there is a greater risk of systemic effects of topical corticosteroids than in adults.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take.
No studies on the interaction of Travocort with other medicines have been conducted.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before using this medicine. The doctor will carefully weigh the benefits and risks for the mother and the fetus.
Pregnancy
Do not use Travocort in the first trimester of pregnancy. The decision to use the medicine in the remaining period of pregnancy is made by the doctor, after assessing the benefit-to-risk ratio. During pregnancy, you should especially avoid using the medicine on large areas of skin, for a long time, or under dressings.
Breastfeeding
It is not known whether Travocort passes into breast milk, but the risk to the health of the breastfed child cannot be excluded.
During breastfeeding, you should avoid using Travocort:
Fertility
There are no data on the negative effect of Travocort on fertility.
It is unlikely that Travocort will affect your ability to drive or use machines.
Travocort contains cetostearyl alcohol, which may cause skin reactions (e.g. contact dermatitis).
Always use this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
A thin layer of Travocort is applied to the affected skin area 2 times a day.
Treatment with Travocort should be stopped when the skin condition improves. The treatment should not last longer than 2 weeks. If necessary, the doctor may continue treatment with an antifungal medicine that does not contain a corticosteroid, especially when using the medicine in the groin and external genital areas.
Hygiene is essential during treatment with Travocort (see section 2).
No dose adjustment of Travocort is necessary in children from 2 years of age and adolescents.
Do not use in children under 2 years of age.
It is unlikely that Travocort will cause acute poisoning after a single use of too much medicine or accidental ingestion.
Do not take a double dose to make up for a forgotten dose.
Take the next dose at the right time and continue treatment as prescribed.
If you have any further questions about using the medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects, observed in clinical trials, are presented according to their frequency:
Common(affect more than 1 in 10 people)
Uncommon(affect more than 1 in 100 people)
Unknown(frequency cannot be estimated from the available data)
Additionally, as with other topical corticosteroids, the following side effects may occur (frequency unknown):
skin thinning (atrophy), folliculitis at the application site, excessive body hair growth, superficial blood vessel dilation (telangiectasia), perioral dermatitis, skin discoloration, acne-like changes, and (or) skin allergic reactions to any of the ingredients of Travocort. Systemic side effects may occur because the ingredients of the medicine penetrate the skin.
It cannot be excluded that side effects may occur in newborns whose mothers used the medicine for a long time during pregnancy or breastfeeding, or used it on large areas of skin.
For example, decreased adrenal cortex function or decreased child immunity to diseases may occur.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
If you experience any side effects, including any not listed in this leaflet, please tell your doctor or pharmacist. Side effects can be reported directly to the Department for Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, e-mail: ndl@urpl.gov.pl.
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Store below 30°C.
Do not use Travocort after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Travocort is a white-yellow, non-transparent cream.
The pack contains an aluminum tube with an HDPE cap, containing 15 g of cream, placed in a cardboard box.
LEO Pharma A/S
Industriparken 55
DK-2750 Ballerup
Denmark
LEO Pharma Manufacturing Italy S.r.l.
Via E. Schering 21
For further information, please contact your doctor or the marketing authorization holder:
LEO Pharma Sp. z o.o.
ul. Marynarska 15
02-674 Warsaw
tel: 22 244 18 40
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.